Table 1

Characteristics for first, additional and combined cohorts (1334 samples)

CharacteristicsFirst cohort (n=1012)Additional cohort (n=322)Combined cohort (n=1334)
M:F, n (%)229 (22.6):783 (77.4)65 (20.2):257 (79.8)294 (22.1):1038 (77.9)
Mean (SD) age at baseline (years)56.5 (11.1)56.7 (10.5)56.6 (10.95)
Mean (SD) disease duration at baseline (years)13.9 (9.8)12.7 (10.2)13.6 (9.89)
Mean (SD) HAQ score at baseline2.05 (0.56)1.9 (0.6)2.0 (0.58)
Current smoker/ex-smoker/never smoked, n (%)171 (16.9)/422 (41.7)/409 (40.4)46 (14.3)/135 (41.9)/137 (42.6)217 (16.3)/557 (41.8)/544 (40.8)
Receiving concurrent DMARD therapy, n (%)720 (71.2)249 (77.3)968 (72.7)
Receiving concurrent steroid therapy, n (%)414 (40.9)127 (39.4)541 (40.6)
Biologic naïve, n (%)949 (93.8)298 (92.6)1246 (93.5)
Mean (SD) baseline DAS286.69 (0.98)6.53 (0.98)6.65 (0.98)
Mean (SD) change in DAS28 at 6-month follow-up−2.47 (1.55)−2.52 (1.40)−2.48 (1.52)
  • DAS28, 28-joint count disease activity score; DMARD, disease-modifying antirheumatic drug; HAQ, Health Assessment Questionnaire.